From: The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer
Parameters | PTC (%) | MNG (%) | Total (%) |
---|---|---|---|
Patients | 60 (66.7) | 30 (33.3) | 90 (100) |
Age | |||
 < 45 years | 43 (71.7) | 10 (33.3) | 53 (58.9) |
 ≥45 years | 15 (25.0) | 17 (56.7) | 32 (35.6) |
Sex | |||
 Male | 15 (25.0) | 5 (16.7) | 20 (22.2) |
 Female | 45 (75.0) | 25 (83.3) | 70 (77.8) |
BRAF V600E mutation | |||
 BRAF (+) | 24 (40.0) | – | – |
 BRAF (−) | 36 (60.0) | – | – |
Tumor size | |||
 < 2 cm | 37 (61.7) | – | – |
 ≥2 cm | 20 (33.3) | – | – |
TNM Staging | |||
 I | 46 (76.7) | – | – |
 II | 3 (5.0) | – | – |
 III | 7 (11.7) | – | – |
 IV | 2 (3.3) | – | – |
Focality Status | |||
 Unifocal | 11 (18.3) | – | – |
 Multifocality | 19 (31.7) | – | – |
Extracapsular invasion | |||
 Yes | 14 (23.3) | – | – |
 No | 45 (75.0) | – | – |
LNM | |||
 Yes | 27 (45.0) | – | – |
 No | 32 (53.3) | – | – |
Lymphovascular invasion | |||
 Yes | 8 (13.3) | – | – |
 No | 51 (85.0) | – | – |
Variant | |||
 Classic | 50 (55.6) | – | – |
 Follicular | 7 (7.8) | – | – |
 Hürthle cell | 1 (1.1) | – | – |
 Sclerosing | 1 (1.1) | – | – |